A high drug failure rate is more than just a pattern recognition problem. Here's how we can address some of the root causes.

Dr Kaitin writes and speaks frequently on factors that contribute to the slow pace and high cost of pharmaceutical R&amp,D and the impact of efforts to speed the drug development process.

Konstanz biologist Patrick Müller receives a Proof of Concept Grant from the European Research Council for his project "EmbryoNet-AI". Its goal is the further development of an AI-supported platform ...

With continued investment and growing buzz from the industry, the AI hype is expected to extend through 2025 and beyond.

The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence ...

In the face of such pressure, pharmaceutical companies are ... to eliminate costly inefficiencies in the drug discovery and development process. The high risk/reward ratio for drug development ...

APAC offers stability in an increasing challenging global geopolitical environment for clinical stage drug development.

A Lloyd's of London company partnered with GATC Health to fund and insure prospective drug trials that pass the test of a new ...

The field of drug discovery faces many time-honored challenges. These include high costs, long development times and high rates of failure. The rise of artificial intelligence (AI) technology has been ...

a degree in the pharmaceutical sciences may be for you. Our undergraduate program focuses on the design, development and rational use of medication for the prevention and treatment of disease, as well ...

Neurocrine Biosciences Inc. has appointed Andrew Ratz, Ph.D. as Senior Vice President of Drug Development, Delivery and ...

3 CDMOs offer a wide range of comprehensive services to pharmaceutical companies, some of which can include supporting formulation development, upscaling current drug processes, clinical trial ...